GE Healthcare Q2 revenue rises 5.7% on Pharmaceutical Diagnostics unit strength
GEHC•Outlook
- GE HealthCare reaffirms 2026 organic revenue growth guidance of 3.0% to 4.0%
- Company expects 2026 adjusted EPS of $4.80 to $5.00
- GE HealthCare anticipates 2026 free cash flow of about $1.6 bln
Result drivers
- SEGMENT PERFORMANCE - Revenue growth was driven by Pharmaceutical Diagnostics and Advanced Imaging Solutions, while Patient Care Solutions continued to face challenges
- TARIFF REFUNDS - Net income and EPS benefited from International Emergency Economic Powers Act tariff refunds recognized in the quarter
- INFLATION PRESSURE - Margins were negatively impacted by inflation related to memory chips, oil and freight costs
Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
- Wall Street's median 12-month price target for GE Healthcare Technologies Inc is $80.00, about 24.8% above its July 28 closing price of $64.11
- The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 14 three months ago
Quarterly results
Related News
General Dynamics tops results estimates on aerospace and marine strength
GD•
Ardmore Shipping Q2 FY26 net income more than doubled to USD 60.5 million; revenue rises 61.35% to USD 116.21 million
ASC•
